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Abstract 
Clinically amyopathic dermatomyositis (CADM), described almost 50 years ago, is defined on the basis of still not 
validated criteria and characterized by skin findings almost without muscle weakness. Autoantibodies directed 
against the cytosolic pathogen sensor MDA5 (CADM 140) can mark this subtype of dermatomyositis which has been 
reported to associate, in particular ethnic groups, with severe progressive interstitial lung disease, poor prognosis and 
an hyperferritinemic status resembling hemophagocytic-like syndromes. MDA5 may be relevant in that Interferon-sig-
nature claimed to characterize inflammatory myopathies and dermatomyosits itself, but its role is not clear. However, 
the titre of anti-MDA5 autoantibodies seems to correlate with the outcome. In Caucasian populations the association 
between anti-MDA5 positive CADM and rapidly progressive interstitial lung disease seems to be weaker, but the lim-
ited numbers of patients described so far could explain the lack of statistical significance. As a fact, European patients 
with circulating anti-MDA5 autoantibodies may be clinically inhomogeneous and exhibit different rates of severity. 
The two patients affected by anti-MDA5 positive dermatomyositis described hereafter provide a clear example of the 
extreme variability of the disease in terms of laboratory findings and clinical features.
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Background
Myositis-specific autoantibodies (MSAs) are closely 
associated with Dermatomyositis (DM), a rare systemic 
autoimmune disease characterized by skin involvement 
and muscle inflammation of variable entity. MSAs are 
mutually exclusive and differently related to clinical man-
ifestations, complications, response to therapy and prog-
nosis [1, 2]. Among them, anti-MDA5 autoantibodies 
have been associated with a subtype of DM with scarce 
muscle inflammation, classical skin disease and highly 
variable systemic manifestations.
We report here two cases of DM recently observed 
in our Department who confirm the high variability in 
the clinical presentation when circulating anti-MDA5 
autoantibodies are present.
Case reports
Patient #1
A 38  years old man from East Europe was admitted in 
our Dept. because of severe heliotrope rash with impres-
sive eyelid oedema (Fig. 1a), mouth ulcerations, Gottron’s 
papules and diffuse Gottron’s sign (Fig. 2a, b), tender pal-
mar papules with signs of necrosis (Fig.  2c, d). Within 
2  days the patient developed severe hypoxemia (pO2 
48 mmHg) and a severe reduction in DLCo (42 %) associ-
ated with radiographic features of alveolitis and ground 
glass, in addition to intense muscle weakness and dys-
phagia. He also started to exhibit high grade continuous 
fever (>39  °C) insensitive to ordinary antipyretics while 
the presence of any infectious agent was excluded. Severe 
leucopenia together with anemia and thrombocytopenia, 
increased muscle and liver enzymes, hyperferritinemia 
were demonstrated (Table  1) while electromyography 
reported only mild myositis. Antinuclear autoantibod-
ies were positive along with anti-MDA5 in association 
with anti-Ro52. Presence of malignancies was excluded. 
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The diagnosis of scarcely myopathic but highly aggressive 
dermatomyositis was thus formulated. High dose steroids 
(iv pulse therapy with 1 gr 6MP for 5 days with slow oral 
taper-out) followed by IVIG (2 g/kg/d over 3 days with a 
second reload after 21 days), oral Cyclosporin A (4 mg/
kg/d) together with hydroxychloroquine (5.4  mg/kg/d) 
were used as therapy with stunning results. Heliotrope 
rash rapidly improved and facial oedema reduced as 
well (Fig. 1b, c). O2 arterial pressure also increased (pO2 
86 mmHg, expected age-related value 92 ± 4 mmHg) and 
amelioration of lung function (DLCo 86 %) was observed 
whereas normalization of ferritin and liver enzymes was 
obtained in a two-months span together with disappear-
ance of anti-MDA5 antibodies. The relationship between 
Fig. 1 Severe involvement of eyelids at the admission into the Dept. (a), after pulse therapy with steroids (b) and during treatment with IVIg, Cyclo-
sporine A and hydroxychloroquine (c)
Fig. 2 Violaceous erythema of the abdomen (a), Gottron’s sign (b), tender palm papules (c) with signs of necrosis (d arrows) of patient #1 at admis-
sion
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ferritin values, considered as the best indicator of disease 
activity, levels of anti-MDA5 (and anti-Ro52 kDa, as con-
trol) autoantibodies and therapeutic interventions are 
depicted in Fig. 3.
Patient #2
A 60 years old Italian woman was admitted in our Dept. 
because of heliotrope rash, Gottron’s sign and papules, 
shawl sign, periungueal teleangectasias, mechanic’s 
hands and subcutaneous calcinosis appeared 2  months 
before. She complained from worsening arthralgias 
(hands, wrists, feet) and generalized asthenia but with-
out frank muscular pain or weakness. Electromyography 
showed mild myopathic signs. Spirometry, CO diffusion, 
arterial blood gas analysis and chest HRCT were unre-
markable showing no sign of interstitial lung disease. 
Further exams excluded a paraneoplastic manifestation. 
Antinuclear antibodies were negative but intense positiv-
ity of anti-MDA5 antibodies was found. Liver and mus-
cle enzymes as well as numbers of blood cells and ferritin 
levels were normal (Table  1), whereas ESR was mildly 
increased (Table  1). The diagnosis of amyopathic der-
matomyositis was formulated and treatment with high 
dose IVIG (2  g/kg/d over 3  days) and methylpredniso-
lone (60 mg with slow tapering) followed by azathioprine 
(1  mg/kg/d) was started rapidly achieving full con-
trol of the manifestations and disappearance of MDA5 
autoantibodies.
The intracellular sensor of foreign nucleic 
acids and interferon‑inducer MDA5 and its role 
in autoimmunity
Melanoma-differentiation-associated gene 5 (MDA5), 
also known as Ifih1 or Helicard, discovered by Andrejeva 
et  al. [3]. in 2004, is as an intracellular pathogen sen-
sor located in the cytosol and belonging to the family 
of RIG-I-like receptors (RLRs) as well as RIG-I [4]. In 
physiological conditions, it binds long-sized (>1000  bp) 
viral double-stranded RNA without any end-specificity 
whereas Poly (I:C) represents its synthetic activator [5]. 
Similarly to RIG-I, MDA5 consists in two N-terminal 
caspase recruitment domains (CARDs), two DExD/H-
box helicase domains and a C-terminal domain (CTD). 
The two helicase domains wrap around dsRNA and 
CTD contacts one of them with the formation of a sort 
of a closed ring around the RNA [6, 7]. MDA5 is thigh-
tly regulated by ATP, as binding induces assembly and 
hydrolysis causes depolymerization, and LGP2, a third 
RLR-member, as able to contact dsRNA but unable to 
signal as CARD-lacking [8, 9]. MDA5 assembly, par-
tially dependent from Lys63- linked ubiquitin, activates 
mithocondrial antiviral signalling protein MAVS (also 
known as CARDIF or VISA or IPS-1) situated on the 
mitochondrial and peroxisomal membranes. At least 11 
MDA5 molecules are necessary to recruit MAVS. CARD 
(on MDA5)-CARD (on MAVS) interaction induces 
polymerization of MAVS which switches from a solu-
ble form into a self-propagating helical fiber [10]. This 
likely remodels organelle membranes and activates the 
expression of several anti-viral defense factors including 
Interferons (IFNs). Along with this, binding of MDA5 
to MAVS also activates the cytosolic protein-kinases 
Ikk and TANK-binding kinase 1 (TBK1) which, in turn, 
activate transcription factors NF-kB, IRF3 and IRF7 [11]. 
These factors translocate into the nucleus inducing the 
expression of several proteins including MDA5 itself, 
thus creating an amplifying inflammatory loop. Physi-
ologically, RLRs are key protectors from RNA viruses, are 
expressed in different cell types (dendritic cells, epithelial 
cells and fibroblasts) and are involved in the production 
Table 1 Comparison between  the laboratory findings 
in the two MDA5+ patients with dermatomyositis
All the values reported were measured at admission in the absence of 
therapy. Anti-nuclear antibodies (ANA) were determined by means of indirect 
immunofluorescence on Hep2 cells (Euroimmun). Anti-MDA5 and anti-Ro52 kDa 
were determined by a validated commercial Immunoblot method (Euroimmun) 
(in brackets, levels of autoantibodies as automatically calculated by the 
EUROLineScan software)
Patient #1 Patient #2 Reference values
Total blood counts
 WBC 1.67 5.17 4–10 × 109/L
 Neutrophils 1.08 1.66 1.5–7.5 × 109/L
 Lymphocytes 0.27 2.67 1–5 × 109/L
 Hb 9.8 12.8 13–16 g/dL
 PLTs 130 217 140–440 × 109/L
Liver enzymes
 AST 244 28 15–37 U/L
 ALT 263 48 12–65 U/L
Cholestasis indexes
 ɣ-GT 399 117 5–85 U/L
 AP 120 92 50–136 U/L
Total bilirubin 0.7 0.5 0.2–1 mg/dL
Muscle enzymes
 LDH 483 255 84–246 U/L
 CPK 662 28 35–232 U/L
 Aldolase 11.2 7.4 <7.3 U/mL
Indexes of inflammation
 ESR 50 41 2–10 mm/h
 CRP <9 <9 <9 mg/L
 Ferritin 4218 292 26–388 ng/mL
Autoantibodies
 ANA 1/640 Neg <1/80
 Anti-MDA5 +++ (72) +++ (58) Neg
 Anti-Ro52 +++ (84) Neg Neg
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of IFN-alfa in addition to pro-inflammatory chemokines 
and cytokines [6, 12].
Overproduction (or abnormal production at certain 
sites) of IFN-alfa has been claimed to be the signature 
of autoimmune diseases (so called ‘IFN-alfa signature’) 
such as systemic lupus erythematosus (SLE), type I dia-
betes and myositis [13–15]. Recognition of foreign or 
host DNA indeed induces IFN-alfa production via Toll-
like receptor (TLR) 9 and/or cytosolic DExD/H-box hel-
icase-containing sensors, but these latter do not include 
RLRs. Thus, the role exerted by MDA5 should be differ-
ent, i.e. altered conformation leading to increased type 
I IFN expression. Along with this, functional genetic 
polymorphisms of MDA5 gene (A946T) associated with 
overactivity have been found in SLE [16, 17] and the 
susceptibility to a systemic autoimmune diseases resem-
bling SLE has been recently confirmed in an experimen-
tal model of MDA5 single coding-change mutation [18]. 
Secondly, Thr946/Thr946 homozygous individuals are at 
risk of type I diabetes. However, as this gene allelic vari-
ation is not pathogenic ‘per se’, alterations in negative 
regulatory genes may be probably necessary for overt 
autoimmune diseases [17]. GWAS studies found MDA5 
polymorphisms in Rheumatoid Arthritis and Multi-
ple Sclerosis, nonetheless loss-of-function mutations 
would be protective against these diseases [19]. Further, 
gain-of-function mutations of MDA5 were identified 
in the monogenic interferonopathy Aicardi-Goutières 
Syndrome (AGS) and neuro-inflammatory phenotypes 
characterized by an IFN-alfa signature. These mutations 
increase basal signalling because of the increased affinity 
to dsRNA or the impaired hydrolysis by ATP, even in the 
absence of foreign RNA [19].
Finally, even if MDA5 overreactivity, followed by 
increased production of IFN-alfa, can only be speculated 
in DM and mechanisms are still undisclosed, it is indeed 
true that titers of anti-MDA5 autoantibodies are directly 
related with disease activity and worse prognosis whereas 
their disappearance indicates disease control thanks 
to therapy [20]. However, it is not clear whether these 
autoantibodies represent a simple epiphenomenon or act 
as agonists on the immune sensor or initiators of cytotox-
icity. In addition, although the role of type I IFNs and cer-
tain RLRs, such as RIG-I, have been recently confirmed 
IVIg 
CyA 4.5 mg/Kg/d 3.5 mg/Kg/d 
HyQ 400 mg/d 200 mg/d 
CS 1 mg/Kg/d Slow tapering 
Fe
rr
iti
n 
 (n
g/
m
l) 
1000 
2000 
3000 
4000 
5000 
A
ug
 1
5 
Se
pt
 1
  
O
ct
 1
5 
 
N
ov
 1
5 
D
ec
 1
5 
Ja
n 
15
 
M
ar
 1
5 
Fe
b 
15
 
D
ec
 1
  
N
ov
 1
  
Se
p 
15
 
100 
60 
50 
40 
30 
20 
10 
A
nti-M
D
A
5 antibodies (A
L
) 
A
nti-R
o52kD
a antibodies (A
L
)  
* 
* 
* * 
* 
Fig. 3 Disease activity and its relationship with autoantibodies. The graphic shows the relationship between ferritin values (ng/ml black triangles) 
as index of disease activity, levels of anti-MDA5 antibodies (red dots) and anti-Ro52 kDa (black asterisks both expressed as Arbitrary Levels, AL), as 
determined by a commercial immunoblot, and therapeutic interventions in patient #1. Normal values of ferritin are below 272 ng/ml (red dotted 
line), levels of autoantibodies are considered as negative below 10, as indicated by the manufacturer (Euroimmun AG). CS corticosteroids (methil-
prednisolone, prednisone); CyA cyclosporine A; IVIg immunoglobulins; HyQ hydroxychloroquine. Upward pointing arrow indicates iv pulse therapy
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in classic DM as found to be expressed at higher levels in 
muscle biopsies and human myotube cultures [21], clini-
cal results from sifalimumab (anti-IFN-alfa mAb) need to 
be confirmed in larger trials as well as circulating IFN-
alfa as a potential biomarker in MDA5-positive dermato-
myositis need to be assessed by adequate protocols [22].
Clinical characteristics of MDA5‑positive 
dermatomyositis
DM is a rare autoimmune disease characterized by skin 
involvement, striate muscle inflammation which may 
include the upper oesophagus and possible damage of 
internal organs frequently marked by the presence of 
autoantibodies [23]. Several autoantibodies have been 
described in inflammatory myopathies and distinguished 
into myosytis-associated (MAA) and myositis-specific 
antibodies (MSA) [1] with recent novelties in this field. In 
particular, cortactin has been recognized as a new target 
antigen in polymyositis and immune-mediated necrotiz-
ing myopathies [24] along with anti-nuclear matrix pro-
tein 2/MJ (NXP2), associated with calcinosis [25] and, 
possibly, ILD [26]. The p155 recognized by anti-TIF-1ɣ 
and the small ubiquitin like modifier activating enzyme 
heterodimer eliciting anti-SAE have been related to 
malignancy in adults and severe course of DM, respec-
tively [1, 25, 27]. Finally, anti-MDA5 (also known as anti-
CADM140) were claimed to mark a DM variant with low 
grade/absent muscle inflammation (amyiopathic dermat-
omyositis) but severe skin manifestations, hyperferritine-
mic status, frequent and rapidly progressive interstitial 
lung disease (ILD) and poor prognosis [28–31].
The term of clinically amyiopathic dermatomyositis 
(CADM) was coined by Pearson [32] almost 50  years 
ago describing those 2–20 % DM patients with skin find-
ings but without muscle weakness. In the early nine-
ties classification criteria of CADM were proposed but 
never validated [33] and association with cancer and ILD 
was found. In a retrospective study from United States 
CADM appeared to mostly be a favourable disease [34] 
but soon after a study reviewing 301 patients underlined 
an unusual frequence of lung involvement (13 %). Inter-
estingly enough, 111 patients in this cohort came from 
Eastern Asia [35].
In addition to heliotrope rash, Gottron and shawl 
sign, skin (and mucosa) involvement actually cov-
ers a wide spectrum of manifestations, including pap-
ules (frequently tender on palm), plaques, nodules and 
ulcerations. Painful ulcers usually localize on extensor 
surface of joints (fingers, elbow, knees), lateral nailfolds 
or digital pulp [36]. They can be also present in classic 
DM (usually below 20  %) but more frequently associ-
ate with malignancy, resistance to immunosuppressive 
therapy or, in Asian populations, lung disease [30]. A 
recent retrospective study partially confirms these find-
ings as ulcers did not significantly associate with myopa-
thy or other classical clinical features of DM (dysphagia, 
Raynaud’s or joint pain) but more commonly affected 
Asian patients. On the other hand, ulcers of finger pulp 
and nailfolds were more frequent in patients with anti-
MDA5 autoantibodies and/or anti-Ro52 kDa [36, 37].
Hyperferritinemia can be a primary condition (hemo-
chromatosis, ferritin gene mutations), expression of pri-
mary or acquired hemophagocytic lymphohistiocytosis 
(HLH) or associated with inflammatory, infectious or 
malignant disorders. In autoimmunity, hemophagocytic-
like syndromes or macrophage activation syndromes 
(MAS) can occur in lupus erythematosus, systemic onset 
of juvenile arthritis, catastrophic anti-phospholipid syn-
drome and adult onset Still’s disease [38]. MAS have 
been rarely described in the setting of DM, both classic 
and amyopathic one and are characterized by a septic-
like spectrum with high fever, hepato-splenomegaly, 
lymphoadenopathies, cytopenias and increased levels of 
transaminases [39, 40]. In the Japanese series of CADM 
patients with circulating anti-MDA5 antibodies, hyper-
ferritinemia was associated with severe ILD and fatal 
outcome with an estimated cut-off as predictor of death 
>1500 ng/ml [31, 41].
The interplay between CADM and interstitial lung 
disease is more intriguing. In the early 2000, several 
case reports from Japan, China and Korea suggested 
that CADM was someway related to severe ILD, rapid 
onset of respiratory failure and death within few months 
from the diagnosis (2–6 mo). Depending from the stud-
ies, 30–60 % of CADM Asian patients had ILD and the 
6-month survival rate was about 40  % despite adequate 
treatment with high dose steroids and immunosup-
pressants [29, 42]. As a fact, in 2005 Sato et al. [30] had 
already described Japanese patients with CADM and 
severe ILD as showing circulating anti-CADM140 anti-
bodies and 4 years later the same group identified MDA5 
as the target antigen [43]. However, ethnicity seems to 
play a fundamental role as suggested by the relationship 
between MDA5 positivity and ILD [29, 44]. Actually, 
aggressive course of DM in the lung has not been con-
firmed by American authors [37].
The demonstration of anti-MDA5 may still represent a 
challenge as the first commercially available immunoblot 
assay was only recently introduced into the market in the 
context of other myositis-specific target antigens. Immu-
noprecipitation using 35S and extractive MDA5 origi-
nally used by Japanese authors [30] has been replaced 
by ELISA assays set up by the use of recombinant mol-
ecules from a home-made cDNA library [20] or a com-
mercial source [45] for coating. The same commercial 
recombinant MDA5 has been also applied in a self-made 
Page 6 of 7Parronchi et al. Clin Mol Allergy  (2015) 13:22 
immunoblot [45]. As a fact, no extensive study com-
paring the efficiency of the different methods to detect 
anti-MDA5 has been produced so far. Anyhow, in the 
last 2 years, DM cases with circulating anti-MDA5 anti-
bodies have been also described in populations of non-
Asian descent. Three studies regarding epidemiology 
and clinical features of anti-MDA5+ DM in European 
Caucasian patients have been published so far. In the 
unique retrospective Italian study of Ceribelli et al. [46], 
anti-MDA5 antibodies were found in 5 of 34 consecu-
tive patients with DM (15  %). This seems to be slightly 
above the percentages found in American studies (6 
and 7 %, respectively) [36, 37]. In a Hungarian cohort of 
337 patients with idiopathic inflammatory myopathies 
including DM, anti-MDA5 antibodies were never found 
[25]. On the other hand, and confirming the Italian data, 
in a large number of DM patients from the Mediterra-
nean area [45], the presence of anti-MDA5 was found in 
12 %, half of them with amyopathic disease. In this study, 
more than 50 % of the patients suffered from rapidly pro-
gressive ILD and showed significant shorter survival rate 
in addition to higher frequency of panniculitis. Interest-
ingly enough and similarly to our patient #1, the Span-
ish Authors found that most of the MDA5+ patients 
with DM and severe ILD also showed circulating anti-
Ro52 autoantibodies in an association which has been 
only recently recognized. Viceversa, probably due to the 
very low number of MDA5+ patients in the Italian study, 
no statistical differences in the severity of skin involve-
ment or mortality was found in MDA5+ in comparison 
with non-MDA5 DM patients and the frequency of ILD 
itself was statistically borderline (p 0.048). It was indeed 
confirmed that MDA5+ patients were more frequently 
amyopathic (p < 0.001) but, again, no differences could be 
demonstrated in digit pulp necrosis, Raynaud’s phenom-
enon or joint pain between the two groups.
Conclusions
The pattern of circulating myositis-specific autoantibod-
ies in Dermatomyositis can provide useful information 
for systemic complications and prognosis of the disease 
even though their precise role in the pathogenesis need 
to be further characterized. Anti-MDA5 autoantibodies 
mark a subtype of DM of high severity in Asians whereas 
a highly variable clinical presentation is seen in the Cau-
casian population. In this latter, however, only a compari-
son between larger numbers of MDA5+ and non-MDA5 
DM patients might confirm whether the spectrum of the 
disease is really related to ethnicity.
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